Transcriptomics and Non-coding RNAs in Heart Failure
A special issue of Biomedicines (ISSN 2227-9059). This special issue belongs to the section "Molecular Genetics and Genetic Diseases".
Deadline for manuscript submissions: closed (30 June 2023) | Viewed by 4745
Special Issue Editor
2. Center for Biomedical Research Network on Cardiovascular Diseases (CIBERCV), Madrid, Spain
Interests: heart failure; acute cellular rejection; Golgi apparatus; cardiomyopathy
Special Issues, Collections and Topics in MDPI journals
Special Issue Information
Dear Colleagues,
Heart failure is a shared chronic phase of cardiac functional impairment secondary to many etiologies and considered a serious global health challenge affecting at least 26 million people worldwide. Although many important advances in therapies and prevention have taken place during the last decade, mortality and morbidity are still high and the quality of life poor. Therefore, there is a need to develop new strategies for the management of this syndrome. In this sense, alterations in the gene expression of different pathways that can lead to heart failure are being studied. Gene expression requires precise regulation through selective and bidirectional transport between the nucleus and the cytoplasm, including membrane proteins, enzymes, ribosomal subunits, and different types of RNAs. Noncoding RNAs are emerging as potent and multifunctional regulators in all biological processes, and step by step, studies are unveiling associations between aberrant noncoding RNA expression and human diseases. Better known are miRNAs, where to date, emerging evidence has demonstrated that abnormal expression is associated with the pathological processes of cardiovascular diseases including heart failure, although their functional roles have not been completely understood. This can be contrasted to the lack of information around the expression of other sRNA as snoRNAs or scaRNAs, especially at the cardiac level.
Dr. Estefanía Tarazón
Guest Editor
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Biomedicines is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- gene expression
- noncoding RNAs
- transcriptomic
- heart failure
